Showing 7,021 - 7,040 results of 21,342 for search '(( significant decrease decrease ) OR ( significant ((nn decrease) OR (a decrease)) ))', query time: 0.70s Refine Results
  1. 7021

    Factors associated with mosquito net integrity. by Job Oyweri (22041452)

    Published 2025
    “…Net type, net age and house wall structures significantly influenced net integrity (p < 0.05). Torn nets were significantly more common in pyrethroid-LLIN households with mud-unplastered [OR=5.323 (95% CI = 1.685–16.816), p = 0.004] and corrugated iron walls [OR=6.31 (95% CI = 2.10–18.93), p < 0.001] and in PBO-LLIN households with mud-unplastered walls [OR=9.823 (95% CI = 1.487–64.898), p = 0.018]. …”
  2. 7022

    LLINs knockdown performance over time. by Job Oyweri (22041452)

    Published 2025
    “…Net type, net age and house wall structures significantly influenced net integrity (p < 0.05). Torn nets were significantly more common in pyrethroid-LLIN households with mud-unplastered [OR=5.323 (95% CI = 1.685–16.816), p = 0.004] and corrugated iron walls [OR=6.31 (95% CI = 2.10–18.93), p < 0.001] and in PBO-LLIN households with mud-unplastered walls [OR=9.823 (95% CI = 1.487–64.898), p = 0.018]. …”
  3. 7023

    Factors affecting PBO-LLINs integrity. by Job Oyweri (22041452)

    Published 2025
    “…Net type, net age and house wall structures significantly influenced net integrity (p < 0.05). Torn nets were significantly more common in pyrethroid-LLIN households with mud-unplastered [OR=5.323 (95% CI = 1.685–16.816), p = 0.004] and corrugated iron walls [OR=6.31 (95% CI = 2.10–18.93), p < 0.001] and in PBO-LLIN households with mud-unplastered walls [OR=9.823 (95% CI = 1.487–64.898), p = 0.018]. …”
  4. 7024

    Net bioefficacy data. by Job Oyweri (22041452)

    Published 2025
    “…Net type, net age and house wall structures significantly influenced net integrity (p < 0.05). Torn nets were significantly more common in pyrethroid-LLIN households with mud-unplastered [OR=5.323 (95% CI = 1.685–16.816), p = 0.004] and corrugated iron walls [OR=6.31 (95% CI = 2.10–18.93), p < 0.001] and in PBO-LLIN households with mud-unplastered walls [OR=9.823 (95% CI = 1.487–64.898), p = 0.018]. …”
  5. 7025

    House structure and status. by Job Oyweri (22041452)

    Published 2025
    “…Net type, net age and house wall structures significantly influenced net integrity (p < 0.05). Torn nets were significantly more common in pyrethroid-LLIN households with mud-unplastered [OR=5.323 (95% CI = 1.685–16.816), p = 0.004] and corrugated iron walls [OR=6.31 (95% CI = 2.10–18.93), p < 0.001] and in PBO-LLIN households with mud-unplastered walls [OR=9.823 (95% CI = 1.487–64.898), p = 0.018]. …”
  6. 7026

    LLINs hole positions over time. by Job Oyweri (22041452)

    Published 2025
    “…Net type, net age and house wall structures significantly influenced net integrity (p < 0.05). Torn nets were significantly more common in pyrethroid-LLIN households with mud-unplastered [OR=5.323 (95% CI = 1.685–16.816), p = 0.004] and corrugated iron walls [OR=6.31 (95% CI = 2.10–18.93), p < 0.001] and in PBO-LLIN households with mud-unplastered walls [OR=9.823 (95% CI = 1.487–64.898), p = 0.018]. …”
  7. 7027

    Specifications of prototypes of RSSCA system. by Ngoc-Hai Vu (22290844)

    Published 2025
    “…Compared to conventional PV systems, the RSSCA offers improved light uniformity, better land-use efficiency, and significantly higher electricity generation. However, in regions with limited direct sunlight, such as Seoul in winter, system performance decreases. …”
  8. 7028
  9. 7029

    Baseline Characteristics of Study Participants. by Swati M. Surkar (8399427)

    Published 2025
    “…The results demonstrate that DT training significantly improves and retains DT performance, likely due to a reduction in cognitive-motor interference. …”
  10. 7030

    Raw and processed data files. by Swati M. Surkar (8399427)

    Published 2025
    “…The results demonstrate that DT training significantly improves and retains DT performance, likely due to a reduction in cognitive-motor interference. …”
  11. 7031
  12. 7032
  13. 7033
  14. 7034

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
  15. 7035

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
  16. 7036

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
  17. 7037
  18. 7038
  19. 7039
  20. 7040